Toby is on vacation, so Jesse and Morgan kick off the show discussing recent performance and the latest Schedule III speculation. Jesse shares data on different portfolios he's tracking that may indicate what types of stocks will perform best in the event we get positive news from the DEA.

Curaleaf Executive Chairman Boris Jordan joins halfway through to discuss the company's uplisting from the CSE to the TSX. Boris shares Curaleaf's roadshow plans, and benefits of the uplisting, and gives his latest perspective on the probabilities and impact of federal reform. 

The show concludes with Morgan explaining the widespread impact of the hemp-derived cannabinoids. This market is beginning to rival the legacy market in scale and impact, especially in states without legal cannabis programs.